"This annual oncology course will provide an overview of the recent advances in the diagnosis and treatment of a wide variety of solid tumors and hematologic malignancies. Case-based discussions will facilitate integration of these advances into routine clinical practice."
Learning and Performance Objectives
This educational activity is intended for medical oncologists, and radiation oncologists, hematologists, as well as physician assistants, nurses and nurse practitioners. This two day conference will provide case-based discussions that will guide the clinicians’ continuing education through structured feedback to improve clinical decision making, clinical knowledge and patient management. This course will provide clinicians with an opportunity to discuss their approach to a case and identify strategies to improve their practice and will serve as a teaching opportunity enabling the assessor to share their professional knowledge and experience.
The intended result of this activity is increased knowledge, competence, performance and skill, and enhanced patient care and improved outcomes. At the conclusion of this activity participants will be able to:
- Summarize the recent advances in management of common hematologic malignancies, aplastic, anemia and amyloidosis.
- Explain the role of immune checkpoint inhibitors in the treatment of advanced malignancies of lung, bladder and head and neck cancers and discuss management of common toxicities.
- Discuss appropriate patient selection for targeted therapies for advanced cancers.
- Implement therapeutic strategies for patients with these diseases based on the most recent advances.
- Recognize and describe the unresolved issues that are the focus of ongoing research in the management of hematologic malignancies, aplastic anemia and amyloidosis.
- Summarize recent and emerging data from key studies in clinical and translational cancer research for the following areas: Hematologic malignancies, breast cancer, genitourinary cancer, gastrointestinal tract cancer, lung cancer, head and neck cancer, soft tissue sarcomas, and central nervous system malignancies.
- Implement strategies designed to improve the quality of cancer care, address barriers to optimal care and enhance the patient experience.
- Include new evidence as appropriate when developing innovative clinical strategies to improve patient outcomes.
- Identify scientific advances that further enhance knowledge of cancer biology and pathogenesis.
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit available for this activity:
Washington University School of Medicine in St. Louis designates this live activity for a maximum of 12.5 AMA PRA Category 1 creditsTM. Learners should claim only the credit commensurate with the extent of their participation in the activity.
This activity is awarded up to 13 ANCC contact hours.
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, that planners, faculty and other persons who may influence content of this CME activity disclose all relevant financial relationships with commercial interests in order for CME staff to identify and resolve any potential conflicts of interest prior to the educational activity. Faculty must also disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation. Detailed disclosures will be made in activity handout materials.